Drugs / 68Ga-RGD
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05543954 | Sep 2022 → Dec 2025 overdue | lung neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05549024 | Aug 2022 → Dec 2025 overdue | brain neoplasm, breast cancer, prostate cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07660406 | Aug → Oct 2024 overdue | keloid | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543954 ↗ |
| Modality | Diagnostic / imaging agent | “single target imaging agent 68Ga-RGD or 68Ga-FAPI PET/CT imaging” NCT05543954 ↗ |
| Route | Intravenous | “Intravenous injection of 68Ga-RGD” NCT05543954 ↗ |